Kailera Q2 FY26 net loss widens to $111.31 million; R&D expenses climb to $101.06 million
KLRA•Second-quarter results
Kailera posted a net loss of $111.31 million, widening from $28.95 million a year earlier.
R&D expenses more than doubled to $101.06 million, driven by higher development, clinical and manufacturing costs plus staffing.
General and administrative costs climbed 82.5% to $20.31 million on higher personnel and professional services spending.
Cash position and pipeline updates
Cash, cash equivalents and marketable securities totaled $1.17 billion, expected to fund operations into mid-2028.
Ribupatide oral IND is active; Phase 3 obesity starts are planned in H1 2027, with ribupatide injection Phase 2b data due mid-2027.
